Optimal dosage regimen of meropenem for pediatric patients based on pharmacokinetic/pharmacodynamic considerations

Drug Metabolism and Pharmacokinetics

Volumn 26, Issue 5, 2011, Pages 523-531

  Ohata, Yuka ^a   Tomita, Yoshiko ^a   Nakayama, Mitsunobu ^a   Kozuki, Tsuneo ^a   Sunakawa, Keisuke ^b   Tanigawara, Yusuke ^c  

^a DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

^b KITASATO UNIVERSITY   (Japan)

^c KEIO UNIVERSITY   (Japan)

Author keywords

T>MIC; Meropenem; Monte Carlo simulation; Pediatrics; PK PD

Indexed keywords

MEROPENEM;

ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; JAPANESE; MALE; MENINGITIS; MINIMUM INHIBITORY CONCENTRATION; PHARMACODYNAMICS; PHASE 3 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; RESPIRATORY TRACT INFECTION; SEPSIS; TREATMENT DURATION; TREATMENT OUTCOME; URINARY TRACT INFECTION;

EID: 80055088020     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.DMPK-11-RG-027     Document Type: Article

References (17)

1. Kuti, J. L., Dandekar, P. K., Nightingale, C. H. and Nicolau, D. P.: Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem. J. Clin. Pharmacol., 43: 1116-1123 (2003).
2. Mattoes, H. M., Kuti, J. L., Drusano, G. L. and Nicolau, D. P.: Optimizing antimicrobial pharmacodynamics: dosage strategies for meropenem. Clin. Ther., 26: 1187-1198 (2004).
3. Li, C., Kuti, J. L., Nightingale, C. H. and Nicolau, D. P.: Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients. J. Clin. Pharmacol., 46: 1171-1178 (2006).
4. Kuti, J. L., Ong, C., Lo, M., Melnick, D., Soto, N. and Nicolau, D. P.: Comparison of probability of target attainment calculated by Monte Carlo simulation with meropenem clinical and micro-biological response for the treatment of complicated skin and skin structure infections. Int. J. Antimicrob. Agents, 28: 62-68 (2006).
5. Santos Filho, L., Eagye, K. J., Kuti, J. L. and Nicolau, D. P.: Addressing resistance evolution in Pseudomonas aeruginosa using pharmacodynamic modeling: application to meropenem dosage and combination therapy. Clin. Microbiol. Infect., 13: 579-585 (2007).
6. Watanabe, A., Fujimura, S., Kikuchi, T., Gomi, K., Fuse, K. and Nukiwa, T.: Evaluation of dosing designs of carbapenems for severe respiratory infection using Monte Carlo simulation. J. Infect. Chemother., 13: 332-340 (2007).
7. Mikamo, H. and Totsuka, K.: The comparison of optimized pharmacodynamic dosing strategy for meropenem using Monte Carlo simulation. Jpn. J. Antibiot., 58: 159-167 (2005).
8. Lee, D. G., Choi, S. M., Shin, W. S., Lah, H. O. and Yim, D. S.: Population pharmacokinetics of meropenem in febrile neutropenic patients in Korea. Int. J. Antimicrob. Agents, 28: 333-339 (2006).
9. Wang, H., Zhang, B., Ni, Y., Kuti, J. L., Chen, B. and Chen, M. and Nicolau, D. P.: Pharmacodynamic target attainment of seven antimicrobials against gram-negative bacteria collected from China in 2003-2004. Int. J. Antimicrob. Agents, 30: 452-457 (2007).
10. Li, C., Du, X., Kuti, J. L. and Nicolau, D. P.: Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections. Antimicrob. Agents Chemother., 51: 1725-1730 (2007).
11. Ariano, R. E., Nyhlén, A., Donnelly, J. P., Sitar, D. S., Harding, G. K. M. and Zelenitsky, S. A.: Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia. Ann. Pharmacother., 39: 32-38 (2005).
12. Du, X., Li, C., Kuti, J. L., Nightingale, C. H. and Nicolau, D. P.: Population pharmacokinetics and pharmacodynamics of meropenem in pediatric patients. J. Clin. Pharmacol., 46: 69-75 (2006).
13. Toyonaga, K., Sunakawa, K., Motohiro, T., Iwai, N., Tanigawara, Y., Endo, H., Sato, Y., Kuroki, H., Minagawa, M., Ishiwada, W., Tajima, T., Iwata, S., Cho, H., Sunaoshi, W., Kato, T., Bamba, M., Wakajima, E., Sugita, K., Yamazaki, T., Kawamura, N., Haruta, T., Furukawa, S., Okada, T., Fujimoto, T., Ishihara, T., Ando, A. and Tsumura, N.: Clinical study of meropenem for infections in the pediatric field. J. Infect. Chemother., 51: 762-781 (2003).
14. Clinical and Laboratory Standards Institute: "Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, " Approved standard M7-A7, CLSI, Wayne, PA. (2006).
15. Beal, S. L., Boeckman, A. J. and Sheiner, L. B.: "NONMEM Users Guides: NONMEM Project Group", University of California, San Francisco (1992).
16. Yamaguchi, K., Ishii, Y., Iwata, M., Watanabe, N., Uehara, N. and Yasujima, M., Kasai, T., Suwabe, A., Yamahata, K., Kaku, M., Kanemitsu, K., Imafuku, Y., Nishiyama, K., Murakami, M., Yomoda, S., Taniguchi, N., Yamada, T., Nomura, F., Watanabe, M., Kanno, H., Aihara, M., Maesaki, S., Hashikita, G., Kondo, S., Misawa, S., Horiuchi, H., Tazawa, Y., Nakashima, H., Takemura, H., Okada, M., Yamazaki, F., Horii, T., Maekawa, M., Baba, H., Ishigo, S., Fujita, N., Komori, T., Ichiyama, S., Iinuma, Y., Maeda, S., Yamanaka, K., Murata, Y., Matsuno, S., Kohno, H., Kinoshita, S., Fujita, J., Negayama, K., Murase, M., Miyamoto, H., Kusano, N., Mihara, E., Itaha, H., Ono, J., Yoshimura, H., Yanagihara, K., Matsuda, J., Saikawa, T. and Hiramatsu, K.: Nationwide surveillance of parenteral antibiotics containing meropenem activities against clinically isolated strains in 2006. Jpn. J. Antibiot., 60: 344-377 (2007).
17. Ikawa, K., Morikawa, N., Ikeda, K., Miki, M. and Kobayashi, M.: Population pharmacokinetics and pharmacodynamics of meropenem in Japanese pediatric patients. J. Infect. Chemother., 16: 139-143 (2010).